Business Trip

Matias and Greg interview Justin Mares, co-founder of TrueMed and Kettle & Fire on current US healthcare and how startups have the opportunity to change the system.In this episode, we discuss:How the US system profits from chronic illnessFixing the food system, environmental toxins, pharma incentives & moreOpportunities for founders building in brain and body health.Contrarian ideas Justin is investing in todayCredits:Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Caitlin Ner & Nico V. Rey Find us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank

Brooks Leitner, MD/PhD, newest partner at PsyMed Ventures and expert in neuroscience from Yale and the NIH, discusses the future of brain health investments. He emphasizes a human-first approach, shifting from animal models to clinical insights. The conversation covers emerging investment areas like therapeutics, diagnostics, and AI-enabled care. Brooks also shares his thoughts on leadership challenges, innovative strategies in personal health, and the evolving landscape of mental health innovations that can reshape therapies and enhance patient care.

Matias and Greg interview Dr. Nir Grossman, one of the world’s leading researchers in neurotechnology. Nir is a lecturer in the Department of Brain Sciences at Imperial College London and a founding fellow of the UK Dementia Research Institute. In this episode, we discuss:What is temporal interference (TI), a non-invasive stimulation methodA comparison of TI with deep brain stimulation (DBS)How physics plays a crucial role in neuroscience innovationTranslating TI academic research to clinical useTI’s role in treating Alzheimer’s, epilepsy, depression, and traumatic brain injuryCredits:Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis,  Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank

Greg and Matias interview Dr. James Adams, professor and autism researcher at Arizona State University and President of Gut-Brain-Axis Therapeutics, on groundbreaking research in autism.In this episode, we discuss:The latest advancements in microbiome therapy for autismHow the gut-brain axis is shaping new therapeutic approachesThe role of nutritional interventions in supporting individuals with autismEnvironmental factors and toxins influencing autism developmentCredits:Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis,  Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank

Matias interviews Elizabeth Horn, founder of the 2m Foundation, on the current state of autism and what can we do about it.In this episode, we discuss:The rising prevalence of autism and its impact on societyHow 2m Foundation is funding research and solutionsEnvironmental and biological factors contributing to autismPhilanthropy and venture capital through the Autism Impact FundCredits:Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis,  Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank

Matias and Greg interview Dana Watt, a Partner at Breakout Ventures, about genetic medicine for brain and mental health.In this episode, we discuss:How genetic therapies work: addressing underlying causes, not just symptomsThe opportunities and challenges for genetic therapies for brain healthExploring effective delivery of genetic payloadsCommercial viability and insurance considerationsCredits:Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis,  Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank

Greg and Matias interview Jay Sanguinetti, founder of Sanmai Technologies, a startup using transcranial focused ultrasound for the treatment of mental health conditions. Jay has a background in academia, having worked at the University of Arizona and started the SEMA Lab (Science Enhanced Mindful Awareness).In this episode, we discuss:The science behind transcranial focused ultrasound and its therapeutic potential for mental healthThe risks and considerations involved in using focused ultrasound technology for mental health treatmentsJay's experience transitioning from academia to founding a mental health technology startupThe regulatory landscape that Sanmai Technologies will navigate as they bring this novel neurotechnology to marketCredits:Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis,  Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank

Greg and Matias interview Tim Marjenin, a regulatory consultant at MCRA with 16 years of experience at the FDA, to discuss the regulatory landscape for neurotechnology devices.Tim provides insights into the FDA approval process for neurotech devices, drawing from his extensive experience on the FDA's Neurostimulation-Neurology Devices Team. The episode explores the evolving field of neurotechnology and its regulatory challenges.In this episode, we discuss:Different regulatory pathways for neurological devices (510(k), De Novo, PMA)FDA's approach to novel neurotechnologies like brain-computer interfaces (BCIs)Considerations for invasive vs. non-invasive neurotech devicesThe importance of cybersecurity in neurotechnologyCommon mistakes companies make in the regulatory process and how to avoid themThe potential future of neurotechnology, including human augmentation and telepathyCreated by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis,  Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank and Krotoa by Makropulos

Greg and Matias interview Gurdane Bhutani, an investor at MBX Ventures, to discuss the impact of environmental toxins on health and the field of exposomics.Gurdane is an expert in environmental health, with a background in Epidemiology and Environmental Health Sciences. He provided insights into the pervasive nature of environmental toxins and their implications for public health. This episode also has a guest appearance from Bruce Blumberg, a Professor of Developmental and Cell Biology at UC Davis.In this episode, we discuss:The widespread presence of environmental toxins and their link to diseases like Parkinson's and autismThe field of exposomics and lifetime environmental exposuresObesogens (chemicals whose exposure makes you fat)Startups building solutions for better diagnostics, green chemistry, and water treatmentPractical lifestyle changes to reduce exposure to harmful chemicals and improve healthCredits:Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis,  Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank and Temperance by Eltham House

In this engaging discussion, Josh Hardman, founder and editor of Psychedelic Alpha, tackles the FDA's recent rejection of MDMA for PTSD therapy. He explores the complexities of the FDA advisory process and highlights the challenges in data gaps and potential biases in clinical trials. Hardman delves into the future of psychedelic treatments and the rising importance of non-hallucinogenic therapies. The conversation also touches on the implications for insurance coverage and regulatory pathways, painting a vivid picture of the evolving landscape in mental health treatment.